Shah Gaurav — SEC insider filings
SEC reporting owner CIK 1725922. 37 insider filings on record with FilingPulse; latest filed 2026-11-20.
Transaction summary — filings shown
Covers all 37 filings on record, filed 2021-02-08 to 2026-11-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 42,000 shares, $483,113 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 20 legs across 20 filings — 189,795 shares, $2,059,029 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 50.
- Largest priced transaction: sale of 20,272 shares @ $29.84 ($604,876) in ROCKET PHARMACEUTICALS, INC., filed 2024-02-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | CEO | 35 | 2 legs · 42,000 sh · $483,113 | 20 legs · 189,795 sh · $2,059,029 | 48 |
| Talaris Therapeutics, Inc. (TALS) | Director | 2 | — | — | 2 |
Insider filings — Shah Gaurav
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 2,216 @ $2.18 | EDGAR |
| 2026-11-17 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 3,020 @ $2.25 | EDGAR |
| 2026-08-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 2,293 @ $3.38 | EDGAR |
| 2026-08-17 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 2,837 @ $3.38 | EDGAR |
| 2026-05-26 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Option exercise (M): 76,490 @ $1.69 · Sale (S): 55,684 @ $3.09 · Option exercise (M): 76,490 (derivative) @ $1.69 | EDGAR |
| 2026-05-21 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 2,409 @ $3.01 | EDGAR |
| 2026-05-14 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 2,728 @ $3.61 | EDGAR |
| 2026-02-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 5,990 @ $3.34 | EDGAR |
| 2026-02-18 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 12,279 @ $3.31 | EDGAR |
| 2026-02-13 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Grant/award (A): 286,028 @ $0 · Grant/award (A): 870,648 (derivative) @ $0 | EDGAR |
| 2025-11-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 6,276 @ $2.98 | EDGAR |
| 2025-08-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Tax withholding (F): 2,234 @ $3.05 | EDGAR |
| 2025-05-22 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 2,253 @ $6.45 | EDGAR |
| 2025-05-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 3,621 @ $6.53 | EDGAR |
| 2025-04-14 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Purchase (P): 20,000 @ $5.08 | EDGAR |
| 2025-02-25 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 16,303 @ $10.58 | EDGAR |
| 2025-02-13 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Grant/award (A): 81,655 @ $0 · Grant/award (A): 243,345 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 11,091 @ $13.05 | EDGAR |
| 2024-08-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 9,650 @ $18.50 | EDGAR |
| 2024-05-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Option exercise (M): 7,979 @ $0 · Option exercise (M): 9,683 @ $0 · Other (J): 23,940 @ $0 · Other (J): 67,785 @ $0 · Sale (S): 9,790 @ $23.35 · Option exercise (M): 7,979 (derivative) @ $0 · +3 more | EDGAR |
| 2024-02-21 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 20,272 @ $29.84 · Grant/award (A): 66,577 @ $0 · Grant/award (A): 196,336 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Option exercise (M): 46,828 @ $0 · Option exercise (M): 7,979 (derivative) @ $0 · Option exercise (M): 38,849 (derivative) @ $0 | EDGAR |
| 2023-11-16 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Option exercise (M): 7,979 @ $0 · Option exercise (M): 7,979 (derivative) @ $0 | EDGAR |
| 2023-08-21 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 4,767 @ $15.47 | EDGAR |
| 2023-08-15 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Option exercise (M): 7,979 @ $0 · Option exercise (M): 7,979 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Talaris Therapeutics, Inc. (TALS) | Grant/award (A): 20,500 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 4,122 @ $21.38 | EDGAR |
| 2023-05-16 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Option exercise (M): 7,979 @ $0 · Option exercise (M): 7,979 (derivative) @ $0 | EDGAR |
| 2023-02-22 | 4/A | ROCKET PHARMACEUTICALS, INC. (RCKT) | Option exercise (M): 31,440 @ $0 · Grant/award (A): 348,590 (derivative) @ $0 · Grant/award (A): 116,317 (derivative) @ $0 · Option exercise (M): 31,440 (derivative) @ $0 | EDGAR |
| 2023-02-22 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Sale (S): 12,194 @ $19.06 | EDGAR |
| 2023-02-16 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Grant/award (A): 348,590 (derivative) @ $0 · Grant/award (A): 116,317 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Talaris Therapeutics, Inc. (TALS) | Grant/award (A): 14,501 (derivative) @ $0 | EDGAR |
| 2022-02-16 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Grant/award (A): 297,037 (derivative) @ $0 · Grant/award (A): 95,275 (derivative) @ $0 | EDGAR |
| 2022-02-08 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Purchase (P): 22,000 @ $17.34 | EDGAR |
| 2021-04-01 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Tax withholding (F): 19,984 @ $41.80 · Tax withholding (F): 8,667 @ $42.80 · Tax withholding (F): 48,732 @ $43.86 · Tax withholding (F): 8,505 @ $44.34 · Option exercise (M): 75,880 @ $1.69 · Tax withholding (F): 3,000 @ $45.59 · +3 more | EDGAR |
| 2021-04-01 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Tax withholding (F): 7,493 @ $45.94 · Tax withholding (F): 5,919 @ $45.21 · Tax withholding (F): 8,872 @ $46.45 · Tax withholding (F): 7,475 @ $47.21 | EDGAR |
| 2021-02-08 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1725922 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs